Dashenlin Pharm Grp Co Ltd (603233) - Total Assets
Based on the latest financial reports, Dashenlin Pharm Grp Co Ltd (603233) holds total assets worth CN¥26.08 Billion CNY (≈ $3.82 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 603233 total equity for net asset value and shareholders' equity analysis.
Dashenlin Pharm Grp Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Dashenlin Pharm Grp Co Ltd's total assets have evolved over time, based on quarterly financial data.
Dashenlin Pharm Grp Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Dashenlin Pharm Grp Co Ltd's total assets of CN¥26.08 Billion consist of 47.6% current assets and 52.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 23.5% |
| Accounts Receivable | CN¥1.70 Billion | 6.4% |
| Inventory | CN¥4.13 Billion | 15.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.99 Billion | 7.5% |
| Goodwill | CN¥3.52 Billion | 13.3% |
Asset Composition Trend (2012–2024)
This chart illustrates how Dashenlin Pharm Grp Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 603233 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dashenlin Pharm Grp Co Ltd's current assets represent 47.6% of total assets in 2024, a decrease from 81.1% in 2012.
- Cash Position: Cash and equivalents constituted 23.5% of total assets in 2024, up from 19.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 4.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 15.6% of total assets.
Dashenlin Pharm Grp Co Ltd Competitors by Total Assets
Key competitors of Dashenlin Pharm Grp Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $504.60 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $563.83 Million |
Dashenlin Pharm Grp Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.96 | 0.92 | 1.52 |
| Quick Ratio | 0.66 | 0.60 | 1.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-487.33 Million | CN¥-1.08 Billion | CN¥2.83 Billion |
Dashenlin Pharm Grp Co Ltd - Advanced Valuation Insights
This section examines the relationship between Dashenlin Pharm Grp Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.03 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 9.6% |
| Total Assets | CN¥26.44 Billion |
| Market Capitalization | $3.11 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Dashenlin Pharm Grp Co Ltd's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Dashenlin Pharm Grp Co Ltd's assets grew by 9.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Dashenlin Pharm Grp Co Ltd (2012–2024)
The table below shows the annual total assets of Dashenlin Pharm Grp Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥26.44 Billion ≈ $3.87 Billion |
+9.60% |
| 2023-12-31 | CN¥24.12 Billion ≈ $3.53 Billion |
+15.75% |
| 2022-12-31 | CN¥20.84 Billion ≈ $3.05 Billion |
+20.22% |
| 2021-12-31 | CN¥17.34 Billion ≈ $2.54 Billion |
+40.58% |
| 2020-12-31 | CN¥12.33 Billion ≈ $1.80 Billion |
+42.21% |
| 2019-12-31 | CN¥8.67 Billion ≈ $1.27 Billion |
+32.66% |
| 2018-12-31 | CN¥6.54 Billion ≈ $956.57 Million |
+12.27% |
| 2017-12-31 | CN¥5.82 Billion ≈ $852.05 Million |
+62.64% |
| 2016-12-31 | CN¥3.58 Billion ≈ $523.89 Million |
+34.67% |
| 2015-12-31 | CN¥2.66 Billion ≈ $389.01 Million |
+12.40% |
| 2014-12-31 | CN¥2.37 Billion ≈ $346.10 Million |
+40.71% |
| 2013-12-31 | CN¥1.68 Billion ≈ $245.96 Million |
+68.67% |
| 2012-12-31 | CN¥996.51 Million ≈ $145.82 Million |
-- |
About Dashenlin Pharm Grp Co Ltd
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.